NCI-designated Consortium Cancer Center
Research to Reality: Dismantling Disparities in Cancer Care
ACS CAN California’s Policy Forum on Research and Health Equity
Wednesday, August 10, 2022, 5:00 p.m. - 6:30 p.m.
Featuring Keynote Speaker John D. Carpten, Ph.D. and Panelists Gladys Arias, Maria Garcia-Jimenez, M.D., MHS, Gillian Gresham, Ph.D., and Elena Martinez, Ph.D., MPH
Moderated by Robert Winn, M.D.
Biorepository and Tissue Technology Shared Resource
Thanks to the generous contribution of the Gleiberman Head and Neck Cancer Center, the Moores Cancer Center, Tissue Technology Shared Resource has recently purchased a Phenocycler-Fusion from AKOYA Biosciences. This technology will play a key role in immuno-oncology research by allowing the study of spatial interactions of tumor and immune cells.
The PhenoCycler™-Fusion allows spatial phenotyping of millions of cells at unprecedented scale and speed. Mapping millions of cells and their interactions in a single intact tissue section facilitates the discovery of rare cell types, cellular neighborhoods, and spatial functional states. Push the frontiers of spatial biology with your team using the PhenoCycler solutions (formerly CODEX®).
Salk Cancer Center - Bench to Bedside to Bench Lecture Series
Combined PARP and immune checkpoint blockade in ovarian cancer
Thursday, August 4, 2022
Panagiotis (Panos) A. Konstantinopoulos, M.D., Ph.D.
Director of Translational Research, Gynecologic Oncology
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Hosted by Geoff Wahl, Ph.D.
DRM Seminar Series
Immune and stromal interactions in the regulation of skeletal muscle disease
Monday, August 8, 2022
3:00 p.m. – 4:00 p.m.
Armando Villalta, Ph.D.
Department of Physiology and Biophysics
University of California, Irvine
Hosted by Rob Signer, Ph.D.
Solid Tumor Therapeutics Program Seminar
Quantitative MRI for Prostate Cancer Detection and Monitoring
Wednesday, August 10, 2022
4:30 p.m. – 5:30 p.m.
Tyler Siebert, Ph.D.
Departments of Radiation Medicine, Bioengineering, and Radiology
University of California, San Diego
For up-to-date meeting information,
direct your questions to firstname.lastname@example.org for more information.
Department of Pharmacology - 2022 Summer Seminars
From GPCR biology to drug-discovery: What have we learnt; is it enough?
Wednesday, August 10, 2022
Location: Leichtag Room # 107
Andrew Tobin, Ph.D.
Professor of Molecular Pharmacology
Institute of Molecular Cell & Systems Biology
Director of the Advanced Research Centre
University of Glasgow
Hosted by JoAnn Trejo, Ph.D., M.B.A.
Professor, Department of Pharmacology
Assistant Vice Chancellor for Health Sciences Faculty Affairs
COMMUNITY OUTREACH AND ENGAGEMENT
August 1–7: California HPV Vaccine Week
Look out for events and information on HPV vaccination learning opportunities! Partner Assembly Member Dr. Akilah Weber is introducing a resolution in the state assembly. Be sure to follow us on Twitter @UCSDCancer_COE for updates. More information to come!
Saturday, August 6, 9:00 a.m. - 1:00 p.m.
Community Catch-Up Vaccination Clinic
Dan McKinney Family YMCA
It’s HPV Vaccine Week, and SD PATH is partnering with YMCA San Diego and Ralphs Pharmacy to catch-up the community on routine vaccinations, including HPV. All are welcome!
Saturday, August 13, 2022
10:00 a.m. - 1:00 p.m.
"Backpack Giveaway and HPV Vaccination Clinic"
Moores Cancer Center is partnering with Assembly Member Dr. Akilah Weber’s office to make HPV vaccinations available via our community partner Champions for Health. Cancer education also will be provided at the event.
Location: Lemon Grove Recreation Center
HIGHLIGHTED FUNDING OPPORTUNITIES
2022 Pediatric Cancer Research – Special Grant Opportunity & Significantly Larger Awards V Scholar or Translational or All-Star
$600,000 - $1,000,00 (depending on mechanism)
PURPOSE OF AWARD: Due to exceptional fundraising levels in 2022, the V Foundation is offering an additional pediatric cancer research grant opportunity. This grant opportunity will be implemented through one of three grant mechanisms: V Scholar, Translational, or All-Star grant types.
To be considered for nomination, please send a 1-page Letter of Intent (LOI) to email@example.com for review by our grants committee. See LOI instructions below; the RFA is attached.
LOIs must be submitted to Angela Ballantyne, Ph.D. in a single PDF by the internal deadline of Thursday, August 11, 2022 at 5:00 p.m. Follow these instructions for the submission of your single PDF:
Cover page: Include your name, degree(s), complete academic title, department, phone number, email address; project title, the specific grant to which you are applying, and a statement of your eligibility per V Foundation guidelines.
Letter of Intent/Research Statement (1 page maximum)
Arial, at least 11-point font, at least 1/2 inch margins all around, one page maximum, including any Figures, Tables, etc. Citations only may be included on a second page.
Briefly describe the nature of the research project, including a brief summary of aims, significance and rationale, preliminary data, and the research plan.
NIH-style biosketch (either old or new format is fine)
Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
Call for LOIs - Curebound Targeted Grants and Cure Prizes
Curebound raises funds year-round for collaborative cancer research, including the signature event, Padres Pedal the Cause. Funds are available to faculty members from the six Curebound-affiliated institutions: Moores (MCC), Salk, Sanford Burnham Prebys (SBP), Rady Children’s Hospital, La Jolla Institute (LJI), and Scripps Research (SR). The goal is to stimulate scientific collaboration, team science, and innovative translational research related to the prevention, diagnosis, or treatment of cancer or pre-cancer.
A PI/Co-PI may submit only one LOI for a Targeted Grant and/or one LOI for a Cure Prize in response to this Fall 2022 Curebound call.
Targeted Grants: Curebound will fund innovative translational oncology discoveries that show promise in advancing to pre-clinical and clinical stages. Targeted Grants will fund continuity of ideas from the investigators’ past line(s) of research, and this should be described in their research plan. Targeted Grants should include collaboration with at least one clinical researcher from UC San Diego Health or Rady Children’s Hospital.
- Applicants will be invited to apply for a Targeted translational grant based on review of submitted LOIs.
- $500,000 for a 1-year award
Cure Prize: Prestigious award with a yearly challenge curated by the Curebound Scientific Advisory Board to fund innovative ground-breaking ideas that will change the course of cancer research and care in San Diego. Cure Prizes are given to teams who present collaborative and/or inter-disciplinary solutions that show near-term (3-5 years) promise of clinical breakthrough and represent “game changers” in the prevention, treatment, and/or cure of cancer.
Applicants will be invited to apply for a Cure Prize based on Curebound Scientific review of submitted LOIs.
$1,000,000 for a 2- to 3-year award (either $500,000/year for 2 years or $333,333/year for 3 years)
IDC Coverage: Curebound allows for a maximum 30% inclusive IDC rate for Curebound Targeted grants and Cure Prizes.
All LOIs must be uploaded to WebGAAS (http://moores.ucsd.edu/Admin/grants-in-aid.asp) in a single pdf by the internal deadline of Monday, August 15, 2022 at 5:00 p.m. Follow these instructions for the submission of your single pdf:
- Cover page with identifying information (the specific opportunity to which you are responding; project title; investigator names, titles, institutions, and emails)
- Letter of Intent/Research Statement (2 page maximum)
Arial, at least 11-point font, at least 1/2 inch margins all around, one page maximum, including any Figures, Tables, etc. Citations only may be included on a 3rd page.
Describe the nature of the research program, including a brief summary of aims, significance and rationale, preliminary data, and the research plan. Please be sure to read the RFA and explicitly state how your project aligns with the intention of each grant type (e.g., as detailed in the RFA, for Targeted Grants, be sure to include how the proposed research is an extension of the investigators’ past research; for Cure Prizes, be sure to include how the project is a near-term (3-5 year) innovative solution per the Challenge.
- NIH-style biosketches for all investigators (preferably in new format)
- 5 pages max
- Include active and pending support
LOIs will be reviewed by Curebound’s Scientific Advisory Board and recommendations will be made to Curebound regarding the most competitive proposals. If selected, the PI should be prepared to complete a full application pursuant to the Curebound RFA (attached) and due on September 30, 2022.
Questions? Contact Amy Spilkin, Ph.D., firstname.lastname@example.org
Deadline for LOIs: Monday, August 15, 2022 at 5:00 p.m. (PST) and Friday, September 30, 2022 at 5:00 p.m. (PST) for RFA (if invited to apply)
2022 Moores Cancer Center Community Outreach & Engagement (COE)
Pilot Project Awards to Stimulate Research in Catchment Area Priority Cancers Request for Proposals (RFP)
PURPOSE: Moores Cancer Center, Community Outreach and Engagement (COE) invites full and associate members, post-docs with an established member mentor, and early-stage investigators from the MCC consortium (UC San Diego, San Diego State University, and La Jolla Institute for Immunology) to submit proposals for pilot awards to support catchment area priority cancer research. Expected return on investment is a successful K-series, R-series, or other similar extramural award as a result of preliminary data generated by pilot award support.
Submissions are required to address one or more catchment area (San Diego County) priority cancers: lung, breast, prostate, colorectal, pancreas, liver, leukemia, and HPV-driven cancers.
2022 COE PILOT AWARD FUNDS AVAILABLE:
- One award up to $50K total costs/year for 1 year is expected to be funded
- A PI or co-PI may submit only one application
- Funds are subject to availability
View the COE Pilot RFA Informational Webinar Recording Here
View Webinar Slides Here
Deadline: August 19, 2022 at 5:00 p.m. (PST)
Hanna and Mark Gleiberman Head and Neck Cancer Center, Request for Applications (RFA) Research Pilot Project Grant Opportunity
Up to $75,000 of direct costs per year may be requested, with the second year of funding contingent on progress during the first year.
PURPOSE: The UC San Diego Health, Hanna and Mark Gleiberman Head and Neck Cancer Center is dedicated to providing support for the care of patients with head and neck cancer and their families. The Center strives to not only provide effective, state of the art head and neck cancer care, but also develop innovative, evidence-based approaches that facilitate novel therapies for head and neck cancer and a productive and healthy life for our patients and their families.
The Gleiberman Head and Neck Cancer Center is seeking applications for pilot project grants under the Gleiberman Head and Neck Cancer Center Pilot Project Grant Award Program that will ultimately improve curative therapy and the quality of care for head and neck cancer patients and their families. Research proposals may target any aspect of head and neck cancer care or head and neck and/or voice disease etiology, diagnosis, therapy.
The Gleiberman Head and Neck Cancer Center is particularly interested in applications from investigators who have not previously been involved in translational head and neck cancer research, but whose fundamental research, possibly involving but not limited to cancer mechanisms or technology development, may be newly applied to head and neck cancer. Applications from junior investigators are strongly encouraged.
Deadline: August 24, 2022 by 5:00 p.m. PST
HHMI Freeman Hrabowski Scholars Program
Awards will cover full salary, benefits, and a research budget of approximately $2M direct for 5 years
This new program will support outstanding basic researchers and physician-scientists who exhibit the strong potential to become leaders in their fields and advance diversity, equity, and inclusion. Eligible research areas include not only all basic biomedical science disciplines, but also plant biology, evolutionary biology, biophysics, chemical biology, biomedical engineering, and computational biology. Applicants must have begun a tenure-track faculty position on or after July 1, 2018 or have accepted an offer for a position that will begin no later than July 1, 2023. Up to 30 awards will be made in 2023; future competitions are anticipated every other year. Watch the recording of an information session.
Applications due: September 28, 2022
OTHER FUNDING OPPORTUNITIES
NIH Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24)
Funding Available: $350,000
Funds are to modernize operations of existing research facilities through the purchase and installation of advanced equipment that enable and enhance a broad range of research-supporting activities. Supported equipment must be used substantially in a laboratory research core facility, animal facility, or similar shared-use research space to ensure broad benefits for the institutional research community. Requests must be justified by research-related demands for the modernization of research-supporting functions or for the advancement of facility operations. Equipment must benefit the larger biomedical research enterprise at the applicant institution and represent a technological step forward.
Internal Limited Submission Deadline: Tuesday, August 9, 2022 at 5:00 p.m. (one submission per institution)
Funding Organization's Deadline: Monday, November 7, 2022
Damon Runyon Cancer Research Foundation Fellowship Award
$60,000 - $66,000 in stipend support for 4 years plus additional educational or scientific expenses and a child dependent allowance
The Damon Runyon Cancer Research Foundation is a leading nonprofit organization that funds brave and bold young cancer researchers.
Damon Runyon views cancer research very broadly: not only the full spectrum of basic questions important to normal human biology and carcinogenesis, but also the development of new platforms and technologies. We encourage all theoretical and experimental research with the potential to provide insight about cancer and the search for cancer causes, mechanisms, therapies, and prevention, for all types of cancer.
Application Deadline: August 15, 2022
NCCN, Pfizer, and EMD Serono Quality of Care Initiative to Improve the Treatment of Locally Advanced or Metastatic Bladder Cancer Patients
The intent of this RFP is to fund individual projects capped at $150,000 (direct
and indirect costs) although smaller, lower-costs projects are
encouraged. Funding greater than $150,000 will be considered for
exceptional proposals with detailed budget justification.
National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (GMG) and EMD Serono to offer a second grant opportunity to support quality improvement projects that will advance the quality of care and include guideline concordant care, and best practices around treatment for patients with locally advanced or metastatic disease (Stage IV, according to the AJCC TNM staging system) bladder cancers.
The intent of the RFP also is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit proposals that describe concepts and ideas around how to improve the quality of care, which include guideline concordant care and best practices for treating patients with locally advanced or metastatic disease bladder cancers.
Submit Proposal by Thursday, August 18, 2022 by 5:00 p.m. ET
Administrative Supplements to Support Cancer Disparity Collaborative Research
Award: $150,000 direct for 1 year
The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to (1) promote new cancer disparities research among investigators who do not normally conduct it and (2) encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. Cancer disparities research includes, but is not limited to, basic, translational, behavioral, observational, interventional, environmental, and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden, and/or response to treatment in racial/ethnic minorities and/or underserved populations.
Deadline: September 6, 2022
Melanoma Funding Opportunity
Melanoma Research Alliance and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) will offer two informational webinars next week to overview our recently announced Special Opportunity RFP for Team Science Awards focused on patient-centric clinical trials.
Webinar One - July 26 at 9:00 a.m. ET - Register Here
Webinar Two - July 28 at 11:00 p.m. ET - Register Here
Two team awards. $1,500,000/each
Deadline: October 5, 2022
Research on Interventions That Promote the Careers of Individuals in the Biomedical Research Enterprise (R01 Clinical Trial Not Allowed)
$250,000 direct costs per year for up to 5 years
This Funding Opportunity Announcement (FOA) encourages applications that propose research designed to test interventions to enhance research-oriented individuals' interest, motivation, persistence and preparedness for careers in the biomedical research workforce. Funded projects are expected to produce research findings that will guide the implementation of interventions in a variety of academic settings and career levels to enhance the diversity of the biomedical research workforce.
Deadline: October 13, 2022
MD22-008 Understanding and Addressing Misinformation among Populations That Experience Health Disparities (R01 - Clinical Trials Optional)
Award: $500K direct/year for up to 5 years
To support research that seeks to (1) understand the underlying mechanisms and (2) test interventions that address and mitigate the impact of health-related misinformation and disinformation on health disparities and the populations that experience health disparities.
Deadline: November 13, 2022
Early-Stage/Advanced/Sustained Development of Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional
Award: $275K unlimited direct costs 2-5 years, depending on mechanism
This component of the NCI's Informatics Technology for Cancer Research (ITCR) Program targets the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum.
Deadline: November 17, 2022
Melanoma Research Alliance (MRA) RFP for Team Science Awards That Target Patient-centric Clinical Trials, Jointly Funded by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA
These awards will fund clinical trials with the potential to provide significant benefit to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.
Letters of Intent due 11:59 p.m. ET, October 5, 2022
Estimated LOI decisions: November 18, 2022
Invited Full Proposals due 11:59 p.m. ET, January 18, 2023
Thursday, September 15, 2022
8:00 a.m. - 6:00 p.m.
UC San Diego, Moores Cancer Center
18th Industry/Academia Next Generation Precision Oncology Symposium
Program agenda coming soon!
Questions? Contact Leisa Sutton at email@example.com.
Thursday to Friday, September 22-23, 2022
Multidisciplinary Head and Neck Cancer Care Conference and 5th New Horizons in Immunotherapy
Location: San Diego Marriott Marquis, San Diego, CA
333 West Harbor Drive, San Diego, CA 92101
Tuesday, October 11, 2022
UC San Diego, Moores Cancer Center
Delivering Discoveries Annual Scientific Retreat
Location: Scripps Seaside Forum
8610 Kennel Way, La Jolla, CA 92037
Thursday to Friday, October 20-21, 2022
Sanford Stem Cell Annual Symposium co-hosted by Moores Cancer Center, Hematologic Malignancies Program
Location: Sanford Consortium, Duane J. Roth Auditorium
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
- Recent breakthroughs in regenerative medicine
- Stem cell regeneration in several disease areas
Interactive discussion panels regarding stem cells in space and stem cell clinical trials
Catriona Jamieson, M.D., Ph.D., Deputy Director of Moores Cancer Center, Director of the Sanford Stem Cell Clinical Center, and Chief of the Division of Regenerative Medicine and Alysson Muotri, Ph.D., Co-Director, Stem Cell Program
Derrick Rossi, Ph.D., Co-Founder, Moderna; Elizabeth Blackburn, Ph.D., Professor, UC San Francisco; and Thomas C. Sudhof, M.D., Professor, Stanford University
Friday, October 21, 2022
2:30 – 6:30 p.m.
Hematologic Malignancies Program 2022 Annual Retreat
Location: Sanford Consortium, Duane Roth Auditorium
Catriona Jamieson, M.D., Ph.D. and Thomas Kipps, M.D., Ph.D.
Schedule and more information to come.
Tuesday to Saturday, November 8-12, 2022
Join Us in Person at SITC 2022
37th Annual Meeting and Pre-Conference Programs
Location: Boston Convention and Exhibition Center, Boston, MA. Virtual participation also available at the same registration rates.
Saturday, January 28, 2023
Prostate Cancer Patient Summit
More information to come!
New Hires in the CTO
Madeline Kirkegaard (7/25) - GU Clinical Research Coordinator
Jayamalee De Silva (8/1) - Heme Team Project Manager
Nelson, T. J., Thompson, C. A., Zou, J., Kumar, A., Sangchan, P., Williamson, C. W., Vitzthum, L. K., Sharabi, A. B., Murphy, J. D., Fakhry, C. A., & Mell, L. K. (2022). Validation of NRG Oncology's prognostic nomograms for oropharyngeal cancer in the Veterans Affairs database. Cancer, 128(10), 1948–1957.
Chaim, O.M., Miki, S., Furnari, F., Miyamoto, S. & Brown, J.H. (2022), Regulation of Glioblastoma Stem Cell Properties and Tumor Invasion by G⍺12 Signaling. The FASEB Journal, 36(51).
Thompson, M. C., Harrup, R. A., Coombs, C. C., Roeker, L. E., Pu, J. J., Choi, M. Y., Barr, P. M., Allan, J. N., Šimkovič, M., Leslie, L. A., Rhodes, J., Chong, E. A., Kamdar, M., Skarbnik, A. P., Lansigan, F., McCall, B. J., Saja, K., Dyer, M., Walter, H. S., Lefebure, M., … Mato, A. R. (2022). Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood advances, bloodadvances.2022007812. Advance online publication.
Agarwal, N., McGregor, B., Maughan, B. L., Dorff, T. B., Kelly, W., Fang, B., McKay, R. R., Singh, P., Pagliaro, L., Dreicer, R., Srinivas, S., Loriot, Y., Vaishampayan, U., Goel, S., Curran, D., Panneerselvam, A., Schwickart, M., Choueiri, T. K., & Pal, S. (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). The Lancet. Oncology, 23(7), 899–909.
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center
OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The focus of the research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or industrial environment.
Salary/Stipend Information: NIH stipend scale
See website for more details about CT2 program: WEBSITE
Complete CT2 program application (form available to download from the website above)
One-page personal statement
Proof of U.S. Citizenship/Residency
Three letters of recommendation (one from an identified mentor)
Skills and Knowledge Required: PhD or MD degree, U.S. Citizen or permanent resident status
For more information or to apply, please contact
Amy Spilkin, Ph.D.
Deadline: October 15, 2022
- RA2, Post Award (candidates hired into this position can work remotely, in-person or hybrid). Req #117071
RA3 or RA2, Pre-Award (candidates hired into this position can work remotely, in-person or hybrid). – Req #117444
Financial Analyst 1 – Req #116694
- Financial Analyst 2 – Req #117186
Contracts and Grants Supervisor- Req #117223
- Research and Grant Writer – Req #116068
Want To Be Highlighted in the MCC Newsletter or on the MCC Website?
We want to know and share in each other's successes at Moores Cancer Center. To that end, we are creating a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see highlighted in our MCC weekly newsletter or on the website. Please provide us with the data we need to showcase your great work by completing the Member Highlights Survey linked below.
Thank you in advance for your time!
If you have newsworthy items to contribute, then please contact our Marketing & Communications Manager, Renee Maude at firstname.lastname@example.org.
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC researchers address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. MCC was founded in 1978, the same year it received its NCI designation.
Department of Research Administration
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
This email was sent to .
To continue receiving our emails, add us to your address book.